AZN
BuyPremium GrowerAI neutralAstraZeneca PLC · Healthcare · United Kingdom · $253.3B cap · $460.4M/day traded
$158.33 -0.5% · close 12 Oct · scored 14 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Report expected 30 Oct: the next-year EPS estimate has risen 24.8% over the last 13 weeks.
As of 14 Oct 2026, MoatMap's StockRank for AstraZeneca PLC (AZN) is 76/100, ranked against 24,000+ stocks in 35 markets (Quality 72, Value 45, Momentum 55, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
AstraZeneca is one of the strongest pipeline stories in global pharma, with leading franchises in oncology, rare disease and cardiometabolic drugs. Its forward earnings estimates rose 1.9% over the past month. It has just invested $2 billion in Summit Therapeutics to gain a stake in the PD-1/VEGF antibody class, which extends its oncology reach but pays a high price for a drug still in trials. The business is high quality with defensive earnings, but at a market value of about $253 billion and a middling valuation score (43), the case for large upside from here depends on trial readouts and US drug-pricing policy rather than a clear mispricing.
ABOUT ASTRAZENECA PLC
Read
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines in oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The company boasts a robust pipeline of innovative therapies, strong R&D capabilities, and global market presence, making it a leader in multiple therapeutic areas. Its commitment to breakthrough science provides a significant competitive moat in the healthcare industry.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.4B | 45.8B | 54.1B | 58.7B | 9.8% | 61.4B | 63.3B | 67.2B | 7.0% |
| EPS | 2.12 | 3.84 | 4.54 | 6.60 | 46.0% | 6.69 | 10.05 | 11.32 | 31.0% |
| Shares | 1.5B | 1.6B | 1.6B | 1.6B | +0.1% | 1.6B | — | — | — |
| Debt | 29.1B | 28.4B | 30.1B | 29.1B | 0.0% | 32.3B | — | — | — |
| Equity | 37.0B | 39.1B | 40.8B | 48.7B | 9.5% | — | — | — | — |
| Op CF | 9.8B | 10.3B | 11.9B | 14.6B | 14.1% | 13.7B | — | — | — |
| Inv CF | -3.0B | -4.1B | -8.0B | -6.8B | — | — | — | — | — |
| Fin CF | -6.8B | -6.6B | -4.0B | -7.5B | — | — | — | — | — |
No new 52-week low for 9 weeks, 3% above that low, but not back above a rising 50-day average.
The Momentum score still reads 55: it looks back six months, so it has not caught up with this fall.
Calmer than 79% of stocks we rank over the past year (27% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AZN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AZN | AstraZeneca PLC(you) | $253.3B | 76 | Buy |
| NVS | Novartis AG | $271.3B | 80 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $187.7B | 77 | Buy |
| MRCK34.SA | Merck & Co., Inc. | $360.4B | 78 | Buy |
| NVO | Novo Nordisk A/S | $168.6B | 78 | Buy |
| AMGN | Amgen Inc. | $219.5B | 91 | Strong Buy |
| JNJB34.SA | Johnson & Johnson | $627.4B | 78 | Buy |
| PFE | Pfizer Inc. | $160.6B | 88 | Strong Buy |
| ROP.SW | Roche Holding AG | $351.1B | 92 | Strong Buy |
| GSK | GSK plc | $99.6B | 81 | Strong Buy |
Peer medians: ROE 2.9% · P/E 23.9x · Gross margin 53.8%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.